GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today highlighted the growing strategic importance of scalable domestic vaccine manufacturing infrastructure and diversified vaccine supply capabilities in light of escalating global infectious disease threats.
The World Health Organization's declaration of a Public Health Emergency of International Concern (PHEIC) for the ongoing Ebola outbreak involving the Bundibugyo strain, along with the continued international spread of Clade I mpox and recent hantavirus-related public health concerns, underscore the dynamic nature of global biodefense and pandemic preparedness requirements, according to the company.
“These developments reinforce the importance of scalable and flexible vaccine preparedness infrastructure,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “GeoVax’s primary strategic focus remains the advancement of GEO-MVA, our Modified Vaccinia Ankara (MVA) mpox and smallpox vaccine candidate, which we believe is well aligned with growing global emphasis on diversified vaccine supply, domestic manufacturing capability, and long-term biodefense preparedness.”
GeoVax is advancing GEO-MVA to support global orthopoxvirus preparedness efforts and help address the need for expanded and diversified vaccine supply infrastructure. The company recently announced positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway toward potential regulatory approval. This pivotal Phase 3 trial is scheduled to initiate in the fourth quarter of 2026, with data results anticipated by mid-2027.
GeoVax believes recent infectious disease developments further reinforce the strategic importance of diversified vaccine supply infrastructure, scalable domestic manufacturing capabilities, rapid-response vaccine platform technologies, and long-term investment in biodefense preparedness. The company also noted that the broader applicability of the MVA platform has been demonstrated across multiple infectious disease settings, including prior preclinical Ebola/hemorrhagic fever virus vaccine studies in which GeoVax’s MVA-based Ebola-Zaire vaccine candidate demonstrated complete protection in non-human primate lethal-challenge studies following Ebola virus exposure.
“Recent events continue to demonstrate that preparedness infrastructure cannot remain reactive or narrowly focused on individual outbreak cycles,” continued Mr. Dodd. “We believe the advancement of scalable domestic MVA-based manufacturing capability represents an important strategic objective for strengthening future biodefense readiness.”
For more information about GeoVax and its programs, visit www.geovax.com.
